Microscopy & Imaging: Page 2

3D microscope may replace biopsies with real-time imaging

By Leah Sherwood

The system, called MediSCAPE (Swept Confocally Aligned Planar Excitation microscopy), is capable of capturing images of tissue structures that can guide surgeons to navigate tumors and their boundaries without needing to remove tissues and wait for pathology results. If proven in the field, the technology could eventually replace conventional biopsies and histology with real-time imaging within the living body.

March 28, 2022

PathAI, Cleveland Clinic to build pathology research infrastructure

By LabPulse.com staff writers

The collaboration will combine PathAI's artificial intelligence (AI)-based platforms with Cleveland Clinic's clinical expertise and multimodal data to implement next-generation pathology diagnostics, PathAI said in a news release.

March 9, 2022

Insightec to launch new trials of Exablate Neuro

By LabPulse.com staff writers

One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.

March 9, 2022

AI of chest x-rays finds TB when lab tests fall short

By Leah Sherwood and Erik L. Ridley

As part of the End TB strategy, the World Health Organization (WHO) has recommended the use of chest x-ray as a screening and triage tool where bacteriological diagnostic tests are unclear. Inconclusive TB tests are common in children due to their lower bacteria counts, according to the WHO. The strategy also states that lateral chest x-ray views may be needed in cases of a challenging bacteriological confirmation in younger children.

March 6, 2022

U.K. pathology group expands use of Sectra software

By LabPulse.com staff writers

The NPIC said this expansion will help laboratories in different parts of the U.K. with these efforts. It is a result of a five-year contract signed in October 2021 and is part of a multimillion-pound National Health Service initiative.

March 3, 2022

Spinal fluid tests may aid PET scans of Alzheimer's disease

By Will Morton

A Swiss group led by senior author Michael Schöll, PhD, of the University Gothenburg investigated whether fluid and blood biomarkers that indicate Alzheimer's disease could predict the accumulation of neurofibrillary tau tangles seen on PET scans in patients diagnosed with the disease. They found the lab tests performed well enough to help select patients for PET imaging studies evaluating new treatments.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Brain surface renderings depict Pearson correlation coefficients adjusted for age and sex (r) representing the strength of the association between the different biomarkers and F-18 flortaucipir SUVR change in each brain region. The right upper panel represents age- and sex-adjusted Pearson correlation coefficients (r), along with p-values, for the association between the biomarkers and F-18 flortaucipir SUVR change in the Alzheimer's disease meta-region of interest (ROI). The root mean squared error (RMSE) for the prediction of F-18 flortaucipir SUVR change by a linear model with the biomarker as predictor and age and sex as covariates. RMSE was estimated using leave-one-out cross-validation. Voxel-wise statistical maps were thresholded using more lenient cluster-forming thresholds of p < 0.05 (uncorrected) at the voxel level and further thresholded at the cluster level by restricting results to clusters with a number of voxels higher than the expected number of voxels as predicted using random field theory. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

March 3, 2022

AI developer OxDx raises millions for AI-powered diagnostics

By LabPulse.com staff writers

OxDx said it will use the funds to expand the company and further validate its microscopy and machine-learning technology, which is designed to identify specific series and strains of viruses, bacteria, and other pathogens in a sample within seconds.

February 14, 2022

ContextVision prepares for spinoff of digital pathology arm

By LabPulse.com staff writers

The company is also making other changes to its executive lineup. Katarina Flood will be the firm's chief services officer; Ann-Sofi Hoff, its chief product officer; Gunnar Läthén, its chief technology officer; and Markus Hökerberg as its new chief financial officer.

February 13, 2022

Scopio completes $50M funding round

By LabPulse.com staff writers

The company's workflow digitizes and analyzes blood samples. Its X100 digital slide-scanning device uses computational photography to image entire sample slides and zoom in on individual cells. Its full-field peripheral blood smear application also supports detection, preclassification, and quantification for blood cells. The company is also working on artificial intelligence (AI) applications.

February 10, 2022

Agilent highlights automation platforms at SLAS 2022

By LabPulse.com staff writers

Agilent showcased its BioTek BioSpa live cell analysis system, which provides fully automated live cell imaging workflows in up to eight microplates at a time. It is comprised of a BioTek Cytation C10 confocal imaging reader that combines automated confocal and widefield microscopy with conventional multimode microplate reading and a BioTek BioSpa 8 automated incubator.

February 8, 2022

Digital pathology recovers from COVID setback

By Bruce Carlson

The digital pathology market, which consists of hardware, software, and related services for clinical applications, has largely benefitted from the COVID-19 pandemic, allowing pathologist to read, evaluate, and collaborate remotely, improving efficiency and productivity.

February 2, 2022

Digital pathology offers time savings to pathologists

By Leah Sherwood

Specifically, the digital microscope reduced the time per case for pathologists to make a diagnosis by one minute and 21 seconds per case, amounting to a relative reduction of 26% compared to the light microscope, according to the study, led by Dr. Emily Clarke of the pathology and data analytics division at the University of Leeds in the U.K.

January 24, 2022

Previous Page

Page 2 of 8

Next Page